Vol. 5 No. 1 (2021)

  • Open Access

    Review Article

    Article ID: 35

    Colonic pseudo-obstruction; Ogilvie syndrome; neostigmine; decompression; caecostomy

    by Michael K-Y Hong, Catherine E Turner, David N Blomberg, Matthew J Morgan

    General Surgery, Vol.5, No.1, 2021; 998 Views, 9 PDF Downloads

    Acute colonic pseudo-obstruction is characterised by massive colonic distension without distal mechanical obstruction. It affects a wide variety of patients who often have multiple comorbidities, which makes studies on pseudo- obstruction difficult to perform and interpret. Few advances have been made in recent years in our understanding and management, which remain challenging. This article explores and provides interpretation of the key studies and concepts that have shaped our management of this condition. 

  • Open Access

    Case Report

    Article ID: 69

    Comparison of the Efficacy of Mifepristone and Marvelon Treatment for Perimenopausal Dysfunctional Uterine Bleeding

    by Xiaopin Yang

    General Surgery, Vol.5, No.1, 2021; 844 Views, 4 PDF Downloads

    Objective: To investigate the efficacy of mifepristone and Marvelon treatment for perimenopausal dysfunctional uterine bleeding. Method: 60 patients were randomly selected from January 2016 to June 2016 in our hospital for treatment of menopausal gouthenopsis. After different treatment regimens were communicated with the patients, the patients were treated with different methods. In the experimental group (28 cases), mifepristone was used to treat dysfunctional uterine bleeding. The control group (32 cases) was treated with Marvelon treatment and the results were compared between the two groups. Results: The initial conditions of the two groups were not significantly different (P > 0.05), seen from the levels of folliclein, luteinizing hormone, estrogen and progesterone. After treatment however, the effective rate of the treatment group was significantly higher than the control group (P < 0.05). Conclusion: Mifepristone is effective in the treatment of perimenopausal dysfunction.Â